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Abstract 
Background: Febrile neutropenia (FN) is a major dose-limiting toxicity of cancer chemotherapy resulting in con-
siderable morbidity, mortality, and cost. This study evaluated the time course of neutropenic events and patterns of 
supportive care interventions in patients receiving chemotherapy for early-stage breast cancer treated in oncology 
community practices.
Methods: A prospective cohort study of adult cancer patients initiating a new chemotherapy regimen was con-
ducted at 115 US sites. Toxicity associated with chemotherapy including neutropenic and infectious complications 
was recorded over four cycles. Clinical interventions were recorded including reductions in chemotherapy dose inten-
sity and use of supportive care measures.
Results: A total of 1,202 patients with stage I–III breast cancer were evaluated. The majority of neutropenic (116 of 
196) and infection events (179 of 325) occurred in the initial cycle. A decrease in occurrence of FN and infection was 
observed in the subsequent cycles, along with an increase in utilization of colony stimulating factors (CSFs), antibiot-
ics and reductions in chemotherapy dose intensity. The overall risk of FN in all patients was 16.3%. In patients who 
started treatment at or near full dose intensity, the FN risk reached 21.0% without primary CSF prophylaxis and it was 
9.0% with prophylaxis. There was no significant difference in FN rates by menopausal or hormone receptors status.
Conclusions: The risk of neutropenic complications is greatest in the initial cycle when most patients receive full-
dose chemotherapy. A decrease in neutropenic events during subsequent cycles is associated with reduced dose 
intensity or increased use of supportive care measures. However, the cumulative risk of FN remains high in patients 
with early-stage breast cancer receiving full dose chemotherapy without prophylactic measures.
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Background
Among women, breast cancer is the most prevalent can-
cer type with over a quarter of a million newly diagnosed 
patients annually and accounting for approximately 
40,000 deaths each year in the US, only exceeded by 
lung cancer in terms of cancer-related mortality (Ameri-
can Cancer Society 2015; Gradishar et al. 2015). Largely 
attributable to advancements in diagnostic techniques 
and preventive care, the disease is often detected early 
before the development of evident distant metastases 
(Onitilo et al. 2013). Early-stage breast cancer (ESBC) is 
considered a curable malignancy. However, it is a hetero-
geneous disease with prognosis and also treatment deci-
sions depending on the clinical parameters, molecular 
type, as well as patient’s functional status (Goldhirsch 
et al. 2013; Perou and Borresen-Dale 2011).
An important part of the treatment decision in ESBC 
is whether chemotherapy will be beneficial and if so, the 
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choice of chemotherapy regimen (Theriault et  al. 2013; 
Bonadonna et  al. 2005; Aebi et  al. 2014). All regimens 
before being implemented into the routine clinic practice 
were developed in  a series of clinical trials. Deviations 
from the established schedule either by implementing 
drug dose reductions or treatment delays, resulting in 
reduced relative dose intensity (RDI), may compromise 
treatment outcome (Bonadonna et al. 1995; Budman et al. 
1998; Lyman 2009). When delivered RDI falls below a cer-
tain threshold the patient may get little or no clinical ben-
efit of treatment while still facing multiple burdens from 
myelotoxic treatment (Bonadonna et al. 1995).
Chemotherapy-related toxicities often cause modifi-
cations or interruption of treatment (Lyman et al. 2003, 
2013a). Among the toxicities, chemotherapy-induced 
neutropenia, especially febrile neutropenia (FN), is con-
sidered to be a major adverse event frequently requiring 
hospitalization (Weycker et al. 2014; Kreys et al. 2014). It 
has not only negative effects on treatment schedule but is 
often connected with considerable morbidity, high risk of 
infection-related early mortality, and an increased treat-
ment cost (Hendricks et  al. 2011; Klastersky and Paes-
mans 2011; Kuderer et  al. 2006; Lee et  al. 2015; Pathak 
et al. 2015). Patients have the highest risk of neutropenic 
events at the beginning of treatment, with 50–75% of ini-
tial events happening in the first cycle of chemotherapy 
(Crawford et  al. 2008; Vogel et  al. 2005; Timmer-Bonte 
and Tjan-Heijnen 2006; Gomez et  al. 1998). Moreover, 
patients who have experienced an initial neutropenic 
event are at increased risk for additional neutropenic 
events. Neutropenic or infectious events often generate 
a response from treating clinicians in the management of 
the subsequent cycles with implementing one or more of 
the following options: (1) addition of prophylactic use of 
colony stimulating factors (CSFs); (2) prophylactic use of 
antibiotics; (3) reduction of chemotherapy dose; (4) delay 
in the initiation of the next treatment cycle; (5) interrup-
tion and/or cessation of the planned regimen. Execution 
of any of these measures may decrease the risk of neutro-
penic complications observed in the subsequent cycles 
(Timmer-Bonte and Tjan-Heijnen 2006). However, in a 
curative setting such as ESBC, a decrease in chemother-
apy dose intensity may result in compromised survival 
rates (Bonadonna et al. 1995; Budman et al. 1998).
Patterns of utilization of supportive measures imple-
mented in efforts to reduce neutropenic events during the 
course of chemotherapy within routine community clini-
cal practice are largely unknown. The general population 
receiving chemotherapy includes patients with comor-
bidities, frail or elderly, and may differ from patients with 
cancer treated in randomized control trials (RCTs) who 
are often healthier and highly preselected (Murthy et  al. 
2004). The main aim of this study was to assess timing of 
neutropenic events in relation to clinical interventions such 
as modification of chemotherapy dose or schedule or addi-
tion of supportive care in patients receiving chemotherapy 
treatment in oncology practice within a community setting. 
The data from a prospective observational registry study 
were utilized (Crawford et al. 2008) and the report evaluat-
ing all patients with solid tumors or lymphoma was pub-
lished earlier (Culakova et al. 2014). This analysis is focused 
on patients with stage I–III breast cancer.
Methods
Study description
A prospective observational, multi-center cohort registry 
study comprised of adult ambulatory patients with solid 
tumors or lymphoma receiving chemotherapy was con-
ducted between 2002 and 2006. The primary goals of the 
study were to address questions about the frequency and 
severity of treatment-related complications and the use of 
supportive care in cancer patients treated in community-
based practices. There was no treatment intervention man-
dated by the study and choice of the chemotherapy regimen 
and adjunctive supportive care was at the discretion of the 
treating oncologist. Patient eligibility was generally not 
restrictive in order to enroll typical patients cared for in 
community oncology practices, including those who would 
not be eligible for most clinical trials because of advanced 
age or preexisting comorbidities. The study protocol was 
approved by the University of Rochester Research Sub-
jects’ Review Board (Rochester, NY, USA). Data analyses, 
interpretation, and reporting were performed at the Study 
Coordinating Center independent of the funding agency.
Patient population
Participating patients had to be at least 18 years old with a 
diagnosis of ESBC starting a new myelosuppressive chem-
otherapy regimen and anticipated to receive at least four 
cycles. There was no upper age limit for participation and 
no restrictions based on the comorbid conditions or per-
formance status. The patients had to be willing to return 
for scheduled nadir visits and to sign informed consent. 
In order to lessen the chance of selection bias, sites were 
required to enroll consecutive eligible patients and main-
tain a log of all patients who were offered participation in 
the study. Lactating females, patients treated with con-
tinuous chemotherapy, with active infection, receiving 
concurrent cytotoxic therapy for non-cancer condition, or 
participating in a double blind clinical trial were excluded. 
The analysis presented here is based on patients with avail-
able toxicity data for at least the first cycle of chemotherapy.
Study variables
Demographic information, patient and disease charac-
teristics, comorbid conditions, performance status and 
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data concerning the planned chemotherapy treatment 
were gathered at baseline prior to chemotherapy initia-
tion. Laboratory data, chemotherapy information, and 
concomitant medications were collected at the start 
of each cycle for the first four cycles of chemotherapy. 
Treatment modifications including dose reductions and 
delays as well as supportive care interventions such as 
use of antibiotics and CSFs were captured for each cycle. 
Additionally, laboratory data were collected at the time 
of expected lowest neutrophil counts (nadir), and dur-
ing midcycle visits. Adverse events and chemotherapy-
associated toxicities, including fever and infection, were 
most often recorded at the start of the subsequent cycle 
of chemotherapy. Therefore, some data related to adverse 
events and toxicities for cycle 4 may be incomplete. Infec-
tion was determined based on the report of the treating 
physician. Similarly, fever was defined as reported by a 
clinician or the record of a temperature >38.1°C.
Based on type of drugs, dosing and schedule recorded 
at the baseline, chemotherapy regimens were matched 
with recognized standard regimens recommended for 
treatment of ESBC by American Society of Clinical 
Oncology or National Comprehensive Cancer Network 
guidelines in order to determine RDI. The planned, cur-
rent cycle and overall actual RDI were calculated based 
on the doses and schedule planned at the initiation, cycle 
related, and given over the course of four cycles, respec-
tively (Culakova et al. 2014).
Definition of outcomes
Outcomes of interest for this analysis included occur-
rence of FN, occurrence of severe or febrile neutrope-
nia (SN/FN), reductions in RDI, utilization of CSF and/
or antibiotics as primary prophylaxis or overall. SN was 
defined as absolute neutrophil count (ANC) <500/mm3 
and FN as ANC <1,000/mm3 with reported fever or 
infection in the same chemotherapy cycle. Primary CSF 
prophylaxis was defined as CSF use planned at the begin-
ning of the first cycle or prior to a neutropenic event 
within the first cycle. For subsequent cycles, patients 
were considered to be treated prophylactically with CSF 
if it was reported before or at the baseline of the cycle.
Statistical methods
The goal of this prospective cohort study was to describe 
the frequency and time course of treatment-related com-
plications and patterns of clinical management including 
supportive care and was, therefore, primarily descriptive 
in nature. Clinically relevant variables were summarized 
using standard descriptive statistics utilizing propor-
tions for categorical variables, and measures of central 
tendency and variability summarized as mean, median, 
and/or standard error (SE) for continuous variables. 
Neutropenic events were assessed as proportions of 
patients with an event and were measured by cycle as 
well as cumulatively across cycles. Similarly, propor-
tions of patients receiving supportive care were reported. 
To evaluate the timing of neutropenic events and clini-
cal interventions aimed at preventing them, hazard rates 
were estimated using actuarial methods. Statistical analy-
sis was conducted using SAS version 9.3 (SAS Institute 
Inc.; Cary, NC, USA).
Results
Study participants
This prospective cohort study enrolled 4,458 patients 
with cancer, including 1,224 with ESBC, from 115 ran-
domly selected practice sites located through the entire 
US (37 in Central US, 22 in Northeast, 34 in South, and 
22 in West Coast). The analysis presented here is based 
on 1,202 patients (1,996 women and 6 men) with ESBC 
where 22 patients with no toxicity data were excluded. 
Median and mean age were 53  years (range 26–85, 
SE =  0.3), nearly 60% of women were post-menopausal 
and two-thirds had hormone receptor-positive disease. 
The most common comorbidity reported was diabetes 
(8.0%), while 82.8% of patients had Charlson Comorbid-
ity Index of zero. More than 90% (n = 1,104) of patients 
received the first line of chemotherapy which included 
an anthracycline in 942 (85.3%). Patient demographics, 
clinical, disease and treatment characteristics are sum-
marized in Table  1 for the entire cohort and separately 
based on hormone receptor status.
Neutropenic and infectious events
Neutropenic and infectious episodes had the high-
est occurrence during the first cycle of chemotherapy. 
FN events decreased from 9.7% in cycle 1  to  5.7% and 
3.8% in cycles 2 and 3, respectively. Among 196 (16.3%) 
patients who had a FN event during the treatment, 
almost 60% (n = 116) experienced the initial event dur-
ing cycle 1. Overall, 325 (27.0%) patients experienced 
fever or infection during the observation period and for 
a majority (179 out of 325) the initial events occurred in 
cycle 1. Lower rates of infectious events (10.9 and 8.0%) 
were observed in cycles 2 and 3, respectively, compared 
to 14.9% in cycle 1. The same patterns were observed 
for composite events of SN/FN where the incidence 
fell from 32.1% in cycle 1 to approximately 20% in later 
cycles. Overall, 529 (44.0%) patients had SN/FN events 
during the four cycles of chemotherapy and nearly three-
quarters experienced their initial event in the first cycle 
(Fig. 1). The decreasing trend of FN events was observed 
for pre-menopausal (9.9, 4.7, and 3.3% in cycle 1, 2, and 
3, respectively) as well as post-menopausal women (9.6, 
6.5, and 4.3% in cycle 1, 2, and 3, respectively) and also 
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for patients with hormone receptor-positive (8.9, 5.2, and 
4.0% in cycle 1, 2, and 3, respectively) as well as -negative 
disease (11.4, 6.7, and 3.3% in cycle 1, 2, and 3, respec-
tively). While the overall incidence of FN did not differ 
significantly for pre- and post-menopausal women (15.4 
vs. 17.1%) or by positive vs. negative hormone receptor 
status (15.3 vs. 18.1%), the majority of patients in all these 
subgroups experienced their initial FN during the first 
cycle. Infectious events and SN/FN events had similar 
pattern.
Relative dose intensity
For 1,176 (97.8%) patients, it was possible to match the 
treatment regimen with published standard regimen 
and to calculate the RDI. While only 13.4% of patients 
started chemotherapy with RDI <85%, the overall actual 
RDI <85% was observed in 22.2% and RDI fell below 
85% of standard in at least one cycle in 32.5% of patients 
(Table  2). The planned RDI <85% was more frequent 
for patients with body surface area (BSA) >2 m2 (22.4%) 
compared to patients with BSA ≤2 m2 (10.7%). Approxi-
mately 40% of patients with body mass index (BMI) 
≥30  kg/m2 had RDI reduced below 85% in at least one 
cycle compared to 28.1% of patients with BMI <30  kg/
m2. Reduced RDI at the initiation of the treatment as well 
as subsequent reductions were more common in older 
patients and patients with a poor performance status. 
RDI was similar for patients with hormone receptor-pos-
itive and -negative disease.
Supportive care measures
Approximately one-fourth (26.7%) of patients received 
primary prophylaxis with CSFs. The use of CSFs nearly 
doubled in cycle 2, with nearly two-thirds of patients 
(62.1%) receiving CSFs at some point during the four 
cycles of chemotherapy. A similar trend was noted for the 
Table 1 Descriptive characteristics of  the entire cohort 
and stratified by hormonal status
ECOG Eastern Cooperative Group performance status, ER estrogen receptor, PR 
progesterone receptor, MI myocardial infarction, CHF congestive heart failure, A 
doxorubicin, C cyclophosphamide, E epirubicin, F 5-flourouracil, M methotrexate, 
T docetaxel.
a For some variables sample size is smaller due to missing data, including 48 
patients with unknown hormonal status.
Characteristics All patients ER+ or PR+ ER− and PR−
n (%) n (%) n (%)
Totala 1,202 767 387
Age
 <50 years 452 (37.6) 281 (36.6) 150 (38.8)
 50–64 years 546 (45.4) 357 (46.5) 170 (43.9)
 ≥65 years 204 (17.0) 129 (16.8) 67 (17.3)
Menopausal statusa
 Pre-menopausal 486 (40.7) 316 (41.5) 146 (37.8)
 Post-menopausal 709 (59.3) 446 (58.5) 240 (62.2)
Race
 White 961 (80.0) 629 (82.0) 297 (76.7)
 Black 153 (12.7) 88 (11.5) 58 (15.0)
 Other 88 (7.3) 50 (6.5) 32 (8.3)
Baseline body surface area
 ≤2 m2 930 (77.4) 595 (77.6) 298 (77.0)
 >2 m2 272 (22.6) 172 (22.4) 89 (23.0)
Body mass indexa
 <30 kg/m2 769 (64.1) 499 (65.3) 238 (61.5)
 30 to <35 kg/m2 226 (18.8) 136 (17.8) 81 (20.9)
 ≥35 kg/m2 204 (17.0) 129 (16.9) 68 (17.6)
ECOG performance status
 0 937 (78.0) 608 (79.3) 295 (76.2)
 1 241 (20.0) 145 (18.9) 84 (21.7)
 2–4 24 (2.0) 14 (1.8) 8 (2.1)
Stagea
 I 288 (24.1) 188 (24.6) 96 (25.0)
 II 678 (56.7) 437 (57.1) 218 (56.8)
 III 230 (19.2) 140 (18.3) 70 (18.2)
Medical history
 Prior chemotherapy 98 (8.2) 49 (6.4) 46 (11.9)
 Recent surgery 565 (47.0) 354 (46.2) 188 (48.6)
 Diabetes 96 (8.0) 55 (7.2) 36 (9.3)
 CHF or MI 24 (2.0) 16 (2.1) 5 (1.3)
 Lung disease 30 (2.5) 18 (2.3) 11 (2.8)
 History of anemia 85 (7.1) 57 (7.4) 23 (5.9)
Number of comorbidities
 0 1,027 (85.4) 659 (85.9) 329 (85.0)
 1 153 (12.7) 97 (12.6) 49 (12.7)
 ≥2 22 (1.8) 11 (1.4) 9 (2.3)
Chemotherapy treatment
 Standard AC or EC 527 (43.8) 334 (43.5) 170 (43.9)
 Dose dense AC or EC 137 (11.4) 82 (10.7) 51 (13.2)
 CMF 123 (10.2) 90 (11.7) 31 (8.0)
 CAF or CEF 155 (12.9) 105 (13.7) 47 (12.1)
 TAC or TEC 83 (6.9) 54 (7.0) 27 (7.0)
Characteristics All patients ER+ or PR+ ER− and PR−
n (%) n (%) n (%)
 Paclitaxel/docetaxel 68 (5.7) 41 (5.3) 25 (6.5)
 AT or ET 42 (3.5) 22 (2.9) 16 (4.1)
 Other 67 (5.6) 39 (5.1) 20 (5.2)
Table 1 continued
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use of antibiotics. While the use of prophylactic antibi-
otics in cycle 1 was low (3.8%), overall 16.9% of patients 
received antibiotics without the evidence of infection or 
fever (Fig. 2).
First cycle and subsequent cycles
Decreasing rates of FN and infection in later cycles cor-
related with greater reductions in chemotherapy dose 
intensity along with increased use of prophylactic CSFs 
and antibiotics. Figure 3 displays the hazard rates and it 
compares the timing of the initial neutropenic events to 
the timing of implementation of the measures used to 
prevent them.
Reduced dose intensity was associated with fewer FN 
events. For the group of 157 patients who started treat-
ment with planned RDI <85% of standard, rates of FN 
events in cycle 1 were 4.5 and 8.9% overall. In contrast, 
the FN rates were significantly higher (10.6% in cycle 1 
and 17.6% during four cycles) for patients with planned 
RDI ≥85% (n  =  1,019). The overall FN rates reached 
21.0% in 729 patients who started chemotherapy with 
planned RDI ≥85% without primary CSF prophylaxis. 
In this group, the actual overall RDI fell below 85% more 
frequently in post-menopausal patients than pre-men-
opausal patients (18.3 vs. 7.6%) (Fig.  4). There was no 
significant difference in FN rates, use of antibiotics or 
addition of CSFs by menopausal or hormone receptor 
status.
Toxicities and treatment completion
In addition to neutropenic complications, the most 
common reported adverse events were gastrointestinal 
(nausea 54.4%, vomiting 24.3%, diarrhea 14.1%), fatigue 
(50.2%), myalgia (15.1%), and pain (14.8%). Treatment-
related anemia (hemoglobin <10 g/dL) was observed in 
one-quarter of the patients (25.4%), with hemoglobin 
levels <8 g/dL in 21 individuals (1.7%) (Fig. 5). Of 1,202 
ESBC patients, 1,064 (88.5%) completed at least four 
cycles of chemotherapy and, of those, 168 had missing 
toxicity data related to the nadir of cycle 4. Reasons for 
not completing four cycles included treatment toxic-
ity (n  =  26), patient-requested withdrawal (n  =  15), 
disease progression (n  =  15), other medical reasons 
(n = 12), and administrative/protocol-related progres-
sion or loss to follow-up (n = 67). Administrative rea-
sons for dropping out of the study early were related 
to the study protocol including requirements for nadir 
laboratory tests and did not necessarily result in termi-
nation of chemotherapy. Three patients died within the 
first four cycles of chemotherapy with reported causes 






































































Fig. 1 Neutropenic and infectious events during first 4 cycles. Cycle specific events and cumulative events are presented.
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Discussion
In this prospective cohort study of ESBC patients receiv-
ing conventional chemotherapy in a community practice 
setting, the risk of the initial neutropenic complications 
was greatest during the first cycle of chemotherapy. This 
is consistent with reports from other studies (Vogel et al. 
2005; Haim et  al. 2005; Chan et  al. 2011; Martin et  al. 
2006). It is in line with earlier reports utilizing data from 
this prospective study, and it applies across tumors types 
(Crawford et al. 2008; Culakova et al. 2014).
At the initiation of treatment, most patients received 
the full dose of chemotherapy, often with no primary 
prophylaxis with CSFs or antibiotics. The decrease in 
neutropenic events during subsequent cycles was likely 
the result of clinical interventions such as reductions in 
chemotherapy dose intensity and/or the additional use 
of supportive care measures prompted by neutropenic 
events in cycle 1. A recent trial by Aarts et al. tested the 
hypothesis that in order to decrease treatment cost, the 
use of granulocyte colony-stimulating factor (G-CSF) 
may be limited to the initial cycles (Aarts et  al. 2013). 
Breast cancer patients with estimated FN risk above 
20% were randomized to G-CSF prophylaxis with peg-
filgrastim given only in cycle 1 and 2 (experimental 
arm) versus pegfilgrastim in all cycles. In contrast to 
the expected results, in the experimental arm, FN rates 
climbed after G-CSF was discontinued to the maximum 
of 24% in the third cycle, and reached overall risk of 36%, 
compared to 10% rates in the standard arm with contin-
ued prophylaxis.
Hematologic toxicities as well as chemotherapy dose 
intensity are often underreported in the published 
reports of clinical trials (Lyman 2009; Dale et  al. 2003; 
Truong et  al. 2015). A recent systematic review by 
Table 2 Patients with reduced relative dose intensity (RDI) (percent of patients with reductions are presented)
ECOG Eastern Cooperative Group performance status, ER estrogen receptor, PR progesterone receptor, 1+ cycle at least one cycle.
a For some variables sample size is smaller due to missing data.




RDI <85% for  
1+ cycle (%)




RDI <90% for  
1+ cycle (%)
All (n = 1,176)a 13.4 22.2 32.5 17.0 30.5 40.0
Age
 <50 years (n = 443) 12.4 16.0 26.0 15.3 23.5 33.2
 50–64 years (n = 537) 12.5 23.1 34.3 16.0 32.2 40.8




10.4 14.4 23.4 12.9 21.7 30.3
 Post-menopausal 
(n = 690)
15.2 27.4 38.6 19.7 36.4 46.4
ECOG performance status
 0 (n = 917) 12.5 20.9 31.2 15.8 28.8 37.7
 1 (n = 235) 15.3 26.4 35.7 20.0 36.6 47.2
 2–4 (n = 24) 25.0 29.2 50.0 33.3 37.5 54.2
Prior chemotherapy
 No (n = 1,085) 13.1 21.9 32.4 16.7 30.1 39.9
 Yes (n = 91) 16.5 25.3 34.1 20.9 35.2 40.7
Baseline body surface area
 ≤2 m2 (n = 908) 10.7 19.9 30.3 13.9 28.2 38.0
 >2 m2 (n = 268) 22.4 29.9 39.9 27.6 38.4 46.6
Body mass indexa
 <30 kg/m2 (n = 750) 9.5 17.9 28.1 12.5 25.6 35.3
 30 to  <35 kg/m2 
(n = 220)
16.8 30.0 38.6 20.0 36.8 45.0
 ≥35 kg/m2 (n = 203) 23.6 29.6 41.9 30.0 41.9 51.7
Hormone receptorsa
 ER+ or PR+ (n = 753) 13.9 22.0 32.9 18.1 30.3 41.2
 ER− and PR− 
(n = 378)
11.6 22.2 30.4 14.3 29.9 36.5
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Younis et  al. (2012) studied FN rates outside of RCTs 
for two commonly used regimens: (1) docetaxel 75 mg/
m2, cyclophosphamide 600 mg/m2 every 21 days for four 
cycles (TC) and (2) 5-fluorouracil 500 mg/m2, epirubicin 
100  mg/m2, and cyclophosphamide 500  mg/m2 on day 
1 every 21  days for three cycles followed by docetaxel 
100  mg/m2 day 1 every 21  days for three cycles (FEC-
D). The average FN rate was 17% (range 7–33%) for 13 
studies with TC regimen reaching 29% when prophylac-
tic G-CSF was not given, compared to 5% reported in 
the trial (Younis et al. 2012; Jones et al. 2006). Similarly, 
for nine retrospective studies of FEC-D treatment, the 
FN rate was 24% (18–35%) reaching 31% without G-CSF 
prophylaxis compared to 11.2% reported in the PACS-01 
trial (Younis et al. 2012; Roche et al. 2006). In the study 
reported here, 16% of patients developed FN over four 
cycles. While one-fourth of patients received prophy-
lactic CSFs initially, clinical events resulted in the use 
of CSFs in nearly two-thirds of patients over the period 
of observation. In patients initiating treatment with full 
dose chemotherapy and without G-CSF support, the rate 
of FN exceeded 20% and approximately one-half received 
G-CSF after cycle 1. Of note, there were no meaningful 
differences in G-CSF use or in FN events based on meno-
pausal or hormone receptor status in this group.
The safety and efficacy of primary prophylaxis with 
G-CSF in patients with solid tumors including breast 
cancer receiving chemotherapy was established in RCTs 
(Vogel et al. 2005; Timmer-Bonte et al. 2005; Lyman et al. 
2015a). A meta-analysis of RCTs of chemotherapy with or 
without prophylactic G-CSF confirmed significant reduc-
tions in FN, early mortality, and infection-related mortal-
ity (Kuderer et al. 2007). In addition, a systematic review 
of RCTs in patients with breast cancer demonstrated 
significant reductions in FN, early mortality, risk of hos-
pitalization, and use of intravenous antibiotics (Renner 
et  al. 2012). Another meta-analysis reported improved 
overall survival with more intense breast cancer regimens 
supported by G-CSF (Lyman et al. 2013b). While routine 
prophylactic CSFs are recommended in patients at 20% 
or greater risk of FN, the use of prophylactic antibiotics is 
discouraged due to concerns over rising rates of antimi-
crobial resistance (Aapro et al. 2011; Crawford et al. 2013; 
Smith et al. 2006). Current guidelines oppose antimicro-
bial prophylaxis unless prolonged severe neutropenia is 
expected (Flowers et al. 2013). In the study reported here, 
4% of patients received prophylactic antibiotics in the 
absence of fever or infection in cycle 1 increasing to 17% 
over the four cycles observed.
Although neutropenia commonly results from cyto-
toxic chemotherapy and lowering chemotherapy dose 
intensity may reduce the risk of FN, reductions in chem-
otherapy dose intensity may compromise long term 
outcome and shorten overall survival. RCTs as well as 
observational studies have demonstrated the impor-
tance of maintaining chemotherapy dose intensity in the 
curative setting of ESBC (Bonadonna et  al. 1995; Bud-
man et al. 1998; Chirivella et al. 2009; Perez-Fidalgo et al. 
2014). In the study reported here, one-fifth of patients 
received overall RDI below 85% while 13% started the 
treatment with planned RDI <85%. Of note, reduced RDI 
was more common for older patients, patients with poor 
performance status, and obese patients. Planned dose 
reductions were twice as common with BSA >2 m2 com-
pared to those with BSA ≤2 m2. Guidelines on appropri-
ate chemotherapy dosing of obese adult patients with 
cancer recommend dosing based on calculations using 
actual body weight for most cytotoxic agents (Griggs 











































Fig. 2 Cumulative use of colony-stimulating factors and antibiotics 






















Time from Initiation of Chemotherapy (Days) 
Febrile or Severe Neutropenia
Colony-Stimulating Factors (CSFs)
Antibiotics
Reduced Relative Dose Intensity (RDI)
Median follow-up among ESBC patients was 77 days (interquartile range: 63-84 days) 
Fig. 3 Hazard rates of neutropenic events related to hazard rates of 
measures implemented to avoid neutropenic complications.
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of the doses at 2  m2, are discouraged. Most published 
data indicate no increase in treatment-related toxicities 
in obese patients with cancer receiving full dosing esti-
mated by using actual weight (Griggs et al. 2012; Carroll 
et al. 2012). In addition, clinicians are encouraged to use 
the same rules when responding to the toxicities in non-
obese and obese patients (Griggs et al. 2012).
It is important to note limitations to the current study. 
The population of this prospective observational study 
received chemotherapy between 2002 and 2006, and may 
not be representative of chemotherapy regimens and 
supportive care introduced subsequent to that period. 
Importantly, toxicity data including fever, infection, 
and FN for cycle 4 are likely underreported with nearly 
20% of patients completing all four cycles missing toxic-
ity data for the last cycle. Also, patients who discontin-
ued chemotherapy prematurely have incomplete data 
and represent a potentially more vulnerable group with 
higher risk of adverse events. Additionally, only data 
during the first four cycles were captured and long term 
follow-up is not available. Nevertheless, this prospective 
cohort is the largest prospective study of cancer patients 
capturing detailed chemotherapy treatment and its 
complications in the community setting in US oncology 
practices.
Conclusions
In summary, while the risk of neutropenic complica-
tions is greatest in the initial cycle, the cumulative risk 
of neutropenic events remains high in patients receiv-
ing full dose chemotherapy without prophylactic meas-
ures. The apparent reduction in the risk of neutropenic 
complications in subsequent cycles appears to be asso-
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Fig. 4 Neutropenic events versus supportive measures in subgroup of patients with planned RDI ≥85% and no primary prophylaxis with colony-
stimulating factors. Among 729 patients in this subgroup 29 had unknown hormone receptors status and 3 had unknown menopausal status. ER 
estrogen receptor, PR progesterone receptor, RDI relative dose intensity, 1+ cycle at least one cycle.
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dose reductions and treatment delays or the secondary 
use of prophylactic measures including CSFs, antibiotics 
or both. While other patient-, disease-, and treatment-
related factors may also influence toxicity patterns, they 
likely played less of a role in the observed events. Moreo-
ver, most ESBC patients are treated with a curative intent 
and delivery of full-dose chemotherapy is important to 
sustain favorable long term outcome. Nevertheless, the 
influence of patient and provider decisions, as well as 
institutional and payer policies on the observed rates of 
treatment-related toxicities require additional research 
(Lyman et  al. 2015b). Further, the potential impact of 
educational efforts, practice guidelines or pathways as 
well as direct and out of pocket healthcare costs on treat-
ment and supportive care strategies as well as clinical and 
economic outcomes require further investigation.
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